Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02245568) enrolled 913 participants, all of whom received the study treatment LMTM at doses ranging from 100 to 300 mg per day. Of those who started the trial, 60 participants completed it, while 853 did not complete their participation. The trial was measuring adverse events — that is, any new or worsening health problems that occurred after participants started taking the study treatment, including notable changes in laboratory tests, vital signs, or heart monitoring results. The reported data shows that the primary outcome being tracked was the number of participants who experienced serious or non-serious adverse events during the study. According to the results reported on ClinicalTrials.gov, 734 out of 913 participants were recorded as having at least one such adverse event. No secondary outcome measures appear to have been reported in the data submitted to ClinicalTrials.gov for this trial. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Alzheimer's Disease Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must have already completed participation in one of three specific earlier TauRx research studies (TRx-237-005, TRx-237-008, or TRx-237-015) for dementia or probable Alzheimer's disease, including a 4-week follow-up visit at the end of that study
- Alternatively, you must have already completed participation up to Week 52 in a specific earlier TauRx study (TRx-237-007) for a condition called behavioural variant frontotemporal dementia (a type of brain condition affecting behaviour and personality)
- If you are a woman who could become pregnant, you must be willing to use reliable contraception or practice complete abstinence throughout the study
- You (or a legal representative acting on your behalf, if needed) must be able to read, understand, and sign a written consent form agreeing to take part
- You must have an adult caregiver who consents to be involved, can speak the language used at the study site, spends at least 1 hour a day with you at least 3 days a week, is willing to come with you to every study visit, and can confirm you are taking the study medication as directed
- You must be able to follow the study procedures throughout the trial
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a history of difficulty swallowing
- People who are currently pregnant or breastfeeding
- People who have significant abnormal results from lab tests, heart monitoring, or scans, or who have developed a serious illness that the lead doctor believes makes the risks of joining the trial too high
- People who are currently in another clinical trial or plan to join one during this study
- In Germany specifically: people who are required to live in a full-time care or assisted living facility, or whose ability to freely choose to participate may be unduly influenced (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 9 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Participants With Serious or Non-serious Adverse Events
Other options
Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.